JP2017515473A - イオンチャネルモジュレーターおよびその使用 - Google Patents

イオンチャネルモジュレーターおよびその使用 Download PDF

Info

Publication number
JP2017515473A
JP2017515473A JP2016565470A JP2016565470A JP2017515473A JP 2017515473 A JP2017515473 A JP 2017515473A JP 2016565470 A JP2016565470 A JP 2016565470A JP 2016565470 A JP2016565470 A JP 2016565470A JP 2017515473 A JP2017515473 A JP 2017515473A
Authority
JP
Japan
Prior art keywords
antibody
chain variable
variable region
sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016565470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515473A5 (enExample
Inventor
エー ウィリアムズ，ウェンディ
エー ウィリアムズ，ウェンディ
ジョンズ，クラル
ブトン，ジェイムズ
リンレイ，ジョン
ファン，リン
ジャン スニジュダー，ハルム
ジャン スニジュダー，ハルム
庸子 柴田
庸子 柴田
スリドハラン，スドハルサン
グローブス，マリア
ドブソン，クレア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2017515473A publication Critical patent/JP2017515473A/ja
Publication of JP2017515473A5 publication Critical patent/JP2017515473A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016565470A 2014-05-02 2015-05-02 イオンチャネルモジュレーターおよびその使用 Pending JP2017515473A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987929P 2014-05-02 2014-05-02
US61/987,929 2014-05-02
PCT/EP2015/059633 WO2015166105A2 (en) 2014-05-02 2015-05-02 Ion channel modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019166248A Division JP2020018307A (ja) 2014-05-02 2019-09-12 イオンチャネルモジュレーターおよびその使用

Publications (2)

Publication Number Publication Date
JP2017515473A true JP2017515473A (ja) 2017-06-15
JP2017515473A5 JP2017515473A5 (enExample) 2018-04-19

Family

ID=53055033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016565470A Pending JP2017515473A (ja) 2014-05-02 2015-05-02 イオンチャネルモジュレーターおよびその使用
JP2019166248A Pending JP2020018307A (ja) 2014-05-02 2019-09-12 イオンチャネルモジュレーターおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019166248A Pending JP2020018307A (ja) 2014-05-02 2019-09-12 イオンチャネルモジュレーターおよびその使用

Country Status (8)

Country Link
US (2) US10654926B2 (enExample)
EP (2) EP4001310A3 (enExample)
JP (2) JP2017515473A (enExample)
AU (1) AU2015254558B2 (enExample)
BR (1) BR112016025450A2 (enExample)
CA (1) CA2946669A1 (enExample)
ES (1) ES2899754T3 (enExample)
WO (1) WO2015166105A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022548499A (ja) * 2019-08-23 2022-11-21 ユーエヌエム レインフォレスト イノベーションズ 非オピオイド組成物及び疼痛管理のための治療法
US12145991B2 (en) 2018-11-02 2024-11-19 Unm Rainforest Innovations Therapeutic antibody fragments, methods of making, and methods of use

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266690B2 (en) * 2018-02-01 2022-03-08 Nanjing Iaso Biotherapeutics Co., Ltd. Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
WO2020186158A2 (en) * 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
US12123814B1 (en) * 2019-06-14 2024-10-22 Pierce Biotechnology, Inc. G- protein coupled receptor extraction formulations
MX2022005983A (es) * 2019-11-18 2022-09-07 Janssen Biotech Inc Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
EP4228682A4 (en) * 2020-10-16 2024-11-13 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
CN114685657B (zh) * 2020-12-31 2024-08-16 康诺亚生物医药科技（成都）有限公司 一种功能增强型抗体阻断剂的开发及其应用
WO2023114962A1 (en) * 2021-12-16 2023-06-22 Unm Rainforest Innovations Humanized non-opioid composition and therapies for pain management

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504643A (ja) * 1999-04-21 2003-02-04 バイオセプター プロプライアタリー リミテッド 哺乳類における前腫瘍状態および／または腫瘍状態の同定方法
JP2004520025A (ja) * 2000-12-11 2004-07-08 バイオセプター プロプライアタリー リミテッド 前新生物状態および新生物状態を同定するためのｐ２ｙプリン作動性受容体の発現
US20050074819A1 (en) * 2003-10-01 2005-04-07 Japan Health Sciences Foundation Screening method of drug for treatment of neuropathic pain
WO2005107804A1 (ja) * 2004-05-06 2005-11-17 Ono Pharmaceutical Co., Ltd. 呼吸器疾患治療剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6242216B1 (en) * 1997-11-14 2001-06-05 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X2 and P2X4, and methods of production and use thereof
WO2010093061A1 (ja) 2009-02-16 2010-08-19 日本ケミファ株式会社 ジアゼピンジオン誘導体
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504643A (ja) * 1999-04-21 2003-02-04 バイオセプター プロプライアタリー リミテッド 哺乳類における前腫瘍状態および／または腫瘍状態の同定方法
JP2004520025A (ja) * 2000-12-11 2004-07-08 バイオセプター プロプライアタリー リミテッド 前新生物状態および新生物状態を同定するためのｐ２ｙプリン作動性受容体の発現
US20050074819A1 (en) * 2003-10-01 2005-04-07 Japan Health Sciences Foundation Screening method of drug for treatment of neuropathic pain
WO2005107804A1 (ja) * 2004-05-06 2005-11-17 Ono Pharmaceutical Co., Ltd. 呼吸器疾患治療剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ESTELLE TOULME ET AL.: "P2X4 receptors in activated C8-B4 cells of cerebellar microglial origin", J.GEN.PHYSIOL, vol. 135, no. 4, JPN6019008405, 2010, pages 333 - 353, ISSN: 0003994483 *
MAKOTO TSUDA ET AL.: "P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury", NATURE, vol. 424, JPN6019008401, 2003, pages 778 - 783, XP002376086, ISSN: 0003994482, DOI: 10.1038/nature01786 *
MARIA VALENTE ET AL.: "Expression,purification,electron microscopy,N-glycosylation mutagenesis and molecular modeling of hu", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1808, JPN6019008408, 2011, pages 2859 - 2866, XP028316556, ISSN: 0003994485, DOI: 10.1016/j.bbamem.2011.08.025 *
MARK T.YOUNG ET AL.: "Molecular Shape,Architecture,and Size of P2X4 Receptors Determined Using Fluorescence Resonance Ener", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 38, JPN6019008399, 2008, pages 26241 - 26251, XP055205467, ISSN: 0003994481, DOI: 10.1074/jbc.M804458200 *
REBECCA J.GUM ET AL.: "P2X receptor antagonists for pain management:examination of binding and physicochemical properties", PURINERGIC SIGNALLING, vol. Vol.8,Suppl.1, JPN6019008406, 2012, pages 41 - 56, ISSN: 0003994484 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12145991B2 (en) 2018-11-02 2024-11-19 Unm Rainforest Innovations Therapeutic antibody fragments, methods of making, and methods of use
JP2022548499A (ja) * 2019-08-23 2022-11-21 ユーエヌエム レインフォレスト イノベーションズ 非オピオイド組成物及び疼痛管理のための治療法
US12448440B2 (en) 2019-08-23 2025-10-21 Loyota University Of Chicago Compositions comprising antibodies or antibody fragments which bind the P2X4 receptor

Also Published As

Publication number Publication date
BR112016025450A2 (pt) 2017-12-12
WO2015166105A2 (en) 2015-11-05
WO2015166105A3 (en) 2015-12-30
ES2899754T3 (es) 2022-03-14
CA2946669A1 (en) 2015-11-05
AU2015254558A1 (en) 2016-12-08
US10654926B2 (en) 2020-05-19
US20200247885A1 (en) 2020-08-06
EP3137501A2 (en) 2017-03-08
US20170166634A1 (en) 2017-06-15
EP4001310A2 (en) 2022-05-25
EP4001310A3 (en) 2022-08-10
EP3137501B1 (en) 2021-09-29
JP2020018307A (ja) 2020-02-06
AU2015254558B2 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
US20200247885A1 (en) P2x4 antibodies & uses thereof
CN111629754B (zh) 不引起显著红血细胞凝集的抗cd47抗体
JP6103801B2 (ja) Ｔ細胞、免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体およびその使用。
WO2020200196A1 (zh) 抗Claudin18.2抗体及其应用
TW201741340A (zh) Cd47抗體及使用其之方法
JP6448554B2 (ja) 多発性硬化症を予防及び治療するための方法
US10894833B2 (en) Agents, uses and methods for treatment
CN111808194A (zh) 一种结合密蛋白的用于治疗癌症的人源化抗体
CN112752580B (zh) 抗klrg1抗体
US20250129173A1 (en) Prlr antigen-binding protein, preparation method therefor and use thereof
US11834512B2 (en) Inhibiting anti-ENPP1 antibodies
US20250304679A1 (en) Multispecific antibodies targeting cd79b and cd3 and the uses thereof
TW202440643A (zh) 抗人類ｃｘ３ｃｒ１抗體
CN116082513A (zh) 分离的抗原结合蛋白及其用途
JP2024541053A (ja) 単離された抗原結合タンパク質及びその使用
TW202221036A (zh) 抗人類trpv2抗體
EA049153B1 (ru) Антитела к klrg1
JPWO1999060025A1 (ja) 遺伝子組換え抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161102

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161215

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20161215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191126